Cover Image
市場調查報告書

血吸蟲症:開發平台分析

Schistosomiasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251629
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
血吸蟲症:開發平台分析 Schistosomiasis - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 39 Pages
簡介

血吸蟲症是棲息在河川或湖泊等淡水之寄生蟲造成的感染症之一。症狀有高燒、頭痛、咳嗽、造成深紅色發炎的皮膚炎、腹痛、關節痛、肌肉疼痛等。

本報告提供血吸蟲症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

血吸蟲症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;S比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • BioDiem Ltd
  • Concert Pharmaceuticals, Inc.
  • Kancera AB
  • LondonPharma Ltd
  • Merck KGaA

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BDM-I
  • D-Praziquantel
  • 腸血吸蟲症 疫苗
  • L-Praziquantel
  • 血吸蟲症用小分子

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8500IDB

Summary

Global Markets Direct's, 'Schistosomiasis - Pipeline Review, H2 2016', provides an overview of the Schistosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Schistosomiasis
  • The report reviews pipeline therapeutics for Schistosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Schistosomiasis therapeutics and enlists all their major and minor projects
  • The report assesses Schistosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Schistosomiasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Schistosomiasis Overview
  • Therapeutics Development
    • Pipeline Products for Schistosomiasis - Overview
    • Pipeline Products for Schistosomiasis - Comparative Analysis
  • Schistosomiasis - Therapeutics under Development by Companies
  • Schistosomiasis - Therapeutics under Investigation by Universities/Institutes
  • Schistosomiasis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Schistosomiasis - Products under Development by Companies
  • Schistosomiasis - Products under Investigation by Universities/Institutes
  • Schistosomiasis - Companies Involved in Therapeutics Development
    • Kancera AB
    • LondonPharma Ltd
    • Merck KGaA
    • Salvensis
  • Schistosomiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intestinal schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intestinal schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-Praziquantel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Schistosomiasis - Dormant Projects
  • Schistosomiasis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 23, 2013: BioDiem US patent for skin and wound infections
      • Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
      • Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
      • Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
      • Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Schistosomiasis, H2 2016
  • Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Schistosomiasis - Pipeline by Kancera AB, H2 2016
  • Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2016
  • Schistosomiasis - Pipeline by Merck KGaA, H2 2016
  • Schistosomiasis - Pipeline by Salvensis, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Schistosomiasis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Schistosomiasis, H2 2016
  • Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top